Fixed-duration combo therapy shows promise for leukaemia
Overall response rates >95%, regardless of high-risk features, US study shows.
Fixed-duration ibrutinib plus venetoclax is beneficial for patients with chronic lymphocytic leukaemia, including those with high-risk features, according to a study in Clinical Cancer Research.
Dr John Allan, from Weill Cornell Medicine in New York City, and colleagues reported outcomes of fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukaemia in patients with high-risk genomic features — del(17p), TP53 mutation, and/or unmutated immunoglobulin heavy chain (IGHV) — from the CAPTIVATE study.
Participants received three cycles of ibrutinib then 12 cycles of ibrutinib plus venetoclax.
Of the 195 patients, 129 (66%) had one or more high-risk features.
